MSLN-TTC treatment also promoted the migration of CD103+ DCs and the infiltration of CD8+ T cells into the tumor microenvironment, an effect that was further enhanced when the treatment was combined with anti-PD-L1 therapy [15]. Here, CD8A is linked to neoplasm.